靶向治疗:局部 abluminal 沟槽、低剂量西罗莫司洗脱、可降解聚合物冠脉支架(TARGET All Comers):多中心、开放标签、随机非劣效性试验
TARGET All Comers 为前瞻性、多中心、开放标签、随机非劣效性试验,在 10 个欧洲国家 21 个中心纳入 1653 例有症状或无症状、有心肌缺血客观证据且适合经皮冠状动脉介入治疗的冠心病患者,1:1 随机植入 FIREHAWK 或 XIENCE 支架。主要终点为 12 个月靶病变失败(心源性死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建复合终点),XIENCE 对照事件率假定 7%,非劣效界值 3.5%。12 个月靶病变失败 FIREHAWK 组 46/758(6.1%)vs XIENCE 组 45/764(5.9%),差异 0.2%(90%CI -1.9 至 2.2,非劣效 P=0.004;95%CI -2.2 至 2.6,优越性 P=0.88)。血管造影亚组 176 例中,支架内晚期管腔丢失 FIREHAWK 组 0.17 mm(SD 0.48)vs XIENCE 组 0.11 mm(0.52)(P=0.48),绝对差异 0.05 mm(95%CI -0.09 至 0.18,非劣效 P=0.024)。作者结论认为 FIREHAWK 是治疗缺血性冠心病安全有效的替代支架。
要点
- 全 comers 人群中 12 个月靶病变失败率 FIREHAWK 组 6.1%(46/758)vs XIENCE 组 5.9%(45/764),差异 0.2%(90%CI -1.9 至 2.2),达到非劣效(P=0.004)。
- 12 个月缺血驱动血运重建与支架血栓发生率两组无差异。
- 血管造影亚组支架内晚期管腔丢失 FIREHAWK 组 0.17 mm(SD 0.48)vs XIENCE 组 0.11 mm(0.52),P=0.48,绝对差异 0.05 mm(95%CI -0.09 至 0.18),达到非劣效(P=0.024)。
- 研究为开放标签设计,治疗医师和患者未设盲,结局评估者设盲。
- 作者结论认为 FIREHAWK 是临床实践中治疗缺血性冠心病安全有效的替代支架。
适用人群与场景
- 有症状或无症状的冠心病患者,须有心肌缺血的客观证据且适合经皮冠状动脉介入治疗(全 comers 人群)。
- 研究在 10 个欧洲国家 21 个中心开展。
诊断标准与关键阈值
- 主要终点为 12 个月靶病变失败,即心源性死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建的复合终点。
- 非劣效界值为 3.5%,XIENCE 对照事件率假定为 7%。
研究设计与关键结果
- 前瞻性、多中心、开放标签、随机非劣效性试验,2015年12月17日至2016年10月14日随机 1653 例,FIREHAWK 组 n=823、XIENCE 组 n=830;FIREHAWK 组 65 例、XIENCE 组 66 例因随访数据不足被排除分析。
- 12 个月靶病变失败 FIREHAWK 组 46/758(6.1%)vs XIENCE 组 45/764(5.9%),差异 0.2%(90%CI -1.9 至 2.2,非劣效 P=0.004;95%CI -2.2 至 2.6,优越性 P=0.88)。
- 12 个月缺血驱动血运重建与支架血栓发生率两组无差异。
- 血管造影亚组 176 例中,支架内晚期管腔丢失 FIREHAWK 组 0.17 mm(SD 0.48)vs XIENCE 组 0.11 mm(0.52),P=0.48,绝对差异 0.05 mm(95%CI -0.09 至 0.18,非劣效 P=0.024)。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、开放标签、随机非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在需支架植入的缺血性冠心病全 comers 人群中,FIREHAWK 在 12 个月靶病变失败和 13 个月支架内晚期管腔丢失方面非劣效于 XIENCE,是临床实践中安全有效的替代支架。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The FIREHAWK is a drug-eluting stent with a fully biodegradable sirolimus-containing polymer coating localised to recessed abluminal grooves on the stent surface. We investigated clinical outcomes with this targeted, low-dose, biodegradable polymer, sirolimus-eluting stent compared with XIENCE durable polymer, everolimus-eluting stents in an all-comers population.
METHODS: The TARGET All Comers study was a prospective, multicentre, open-label randomised non-inferiority trial done at 21 centres in ten European countries. Patients with symptomatic or asymptomatic coronary artery disease and objective evidence of myocardial ischaemia who qualified for percutaneous coronary intervention were randomised 1:1 to undergo implantation of a FIREHAWK or XIENCE. Randomisation was web-based, with random block allocation and stratification by centre and ST elevation myocardial infarction. Outcome assessors were masked to treatment allocation, but treating physicians and patients were not. The primary endpoint was target lesion failure at 12 months, a composite of cardiac death, target vessel myocardial infarction, or ischaemia-driven target lesion revascularisation. The control event rate for XIENCE was assumed to be 7%, the non-inferiority margin was 3.5%, and the primary analysis was in the intention-to-treat population, censoring patients who did not have either an event before 365 days or contact beyond 365 days. Late lumen loss was the primary endpoint of an angiographic substudy designed to investigate the non-inferiority of the FIREHAWK compared with the XIENCE stent. This trial is registered with ClinicalTrials.gov, number NCT02520180.
FINDINGS: From Dec 17, 2015, to Oct 14, 2016, 1653 patients were randomly assigned to implantation of the FIREHAWK (n=823) or XIENCE (n=830). 65 patients in the FIREHAWK group and 66 in the XIENCE group had insufficient follow-up data and were excluded from the analyses. At 12 months, target lesion failure occurred in 46 (6·1%) of 758 patients in the FIREHAWK group and in 45 (5·9%) of 764 patients in the XIENCE group (difference 0·2%, 90% CI -1·9 to 2·2, pnon-inferiority=0·004, 95% CI -2·2 to 2·6, psuperiority=0·88). There were no differences in ischaemia-driven revascularisation or stent thrombosis rates at 12 months. 176 patients were included in the angiographic substudy, in which in-stent late lumen loss was 0·17 mm (SD 0·48) in the FIREHAWK group and 0·11 mm (0·52) in the XIENCE group (p=0·48), with an absolute difference of 0·05 mm (95% CI -0·09 to 0·18, pnon-inferiority=0·024).
INTERPRETATION: In a broad all-comers population of patients requiring stent implantation for myocardial ischaemia, the FIREHAWK was non-inferior to the XIENCE as assessed with the primary endpoint of target lesion failure at 12 months and in-stent late lumen loss at 13 months. The FIREHAWK is a safe and effective alternative stent to treat patients with ischaemic coronary artery disease in clinical practice.
FUNDING: Shanghai Microport Medical.
参考来源
- Lansky A, Wijns W, Xu B, et al. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet. 2018. PMID: 30190206. doi:10.1016/S0140-6736(18)31649-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。